Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indications

Introduction Antidepressants such as amitriptyline, bupropion and agomelatine are widely used not only in the treatment of depression, but also in other conditions. Their mechanisms of action affect different neurotransmitter systems, allowing their use in the treatment of pain, addiction or sle...

Full description

Saved in:
Bibliographic Details
Main Authors: Piotr Czerniak, Julia Buszek, Michał Medygrał, Przemysław Koszuta, Małgorzata Dydoń-Pikor, Katarzyna Pajdak-Gicala, Maciej Kawecki, Adrianna Antoszewska, Weronika Bargiel, Sylwia Buszek
Format: Article
Language:English
Published: Nicolaus Copernicus University in Toruń 2025-03-01
Series:Quality in Sport
Subjects:
Online Access:https://apcz.umk.pl/QS/article/view/58924
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850028323255615488
author Piotr Czerniak
Julia Buszek
Michał Medygrał
Przemysław Koszuta
Małgorzata Dydoń-Pikor
Katarzyna Pajdak-Gicala
Maciej Kawecki
Adrianna Antoszewska
Weronika Bargiel
Sylwia Buszek
author_facet Piotr Czerniak
Julia Buszek
Michał Medygrał
Przemysław Koszuta
Małgorzata Dydoń-Pikor
Katarzyna Pajdak-Gicala
Maciej Kawecki
Adrianna Antoszewska
Weronika Bargiel
Sylwia Buszek
author_sort Piotr Czerniak
collection DOAJ
description Introduction Antidepressants such as amitriptyline, bupropion and agomelatine are widely used not only in the treatment of depression, but also in other conditions. Their mechanisms of action affect different neurotransmitter systems, allowing their use in the treatment of pain, addiction or sleep disorders. Amitriptyline, which is a tricyclic antidepressant, has strong analgesic effects. Bupropion, a dopamine and norepinephrine reuptake inhibitor, helps in the treatment of addiction and ADHD. Agomelatine, a melatonin receptor agonist, has been shown to regulate diurnal rhythms, making it useful in the treatment of insomnia and other sleep disorders.   Aim of the Study The aim of this study is to analyse the use of amitriptyline, bupropion and agomelatine in the treatment of conditions other than depression, with a focus on their mechanisms of action and clinical efficacy.   Materials and Methods An analysis of PubMed papers was conducted using keywords: antidepressants, tricyclic antidepressants, SSRI, amitriptyline, bupropion, agomelatine.   Basic Results Amitriptyline is highly effective in the treatment of neuropathic pain, migraines and insomnia due to its potent action on serotonin and histamine receptors. Bupropion is used in the treatment of nicotine addiction and ADHD, as it acts on the dopaminergic and noradrenergic systems to improve concentration and impulse control. Agomelatine, as a melatonin receptor agonist, is used to regulate diurnal rhythms, making it helpful in the treatment of sleep disorders and adaptation to time zone changes. Each of these drugs has unique properties that go beyond their primary use in depression.
format Article
id doaj-art-44f211ca44bd40ac99835fbfe57a48d0
institution DOAJ
issn 2450-3118
language English
publishDate 2025-03-01
publisher Nicolaus Copernicus University in Toruń
record_format Article
series Quality in Sport
spelling doaj-art-44f211ca44bd40ac99835fbfe57a48d02025-08-20T02:59:52ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-03-013910.12775/QS.2025.39.58924Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indicationsPiotr Czerniak0https://orcid.org/0009-0007-3582-4586Julia Buszek1https://orcid.org/0009-0001-3832-2668Michał Medygrał2https://orcid.org/0009-0000-8723-2186Przemysław Koszuta3https://orcid.org/0009-0001-0988-4813Małgorzata Dydoń-Pikor4https://orcid.org/0009-0009-1976-1516Katarzyna Pajdak-Gicala5https://orcid.org/0009-0007-3234-8115Maciej Kawecki6https://orcid.org/0009-0000-0708-5316Adrianna Antoszewska7https://orcid.org/0009-0009-4518-1726Weronika Bargiel8https://orcid.org/0009-0008-5907-8159Sylwia Buszek9https://orcid.org/0009-0007-7214-7991Uniwersytet RzeszowskiUniwersytet RzeszowskiUniwersytet RzeszowskiArtdentis, Zapiecek 16, 97-200 Tomaszow Mazowiecki, PolandMedical University of Silesia, ul. Poniatowskiego 15, 40-055 Katowice, PolandMedical University of Silesia, ul. Poniatowskiego 15, 40-055 Katowice, PolandMedical University of Warsaw, ul. Zwirki i Wigury 61, 02-091 Warsaw, PolandUniwersytet RzeszowskiUniwersytet RzeszowskiFrederic Chopin University Clinical Hospital in Rzeszow Fryderyka Szopena 2, 35-055 Rzeszow, Poland Introduction Antidepressants such as amitriptyline, bupropion and agomelatine are widely used not only in the treatment of depression, but also in other conditions. Their mechanisms of action affect different neurotransmitter systems, allowing their use in the treatment of pain, addiction or sleep disorders. Amitriptyline, which is a tricyclic antidepressant, has strong analgesic effects. Bupropion, a dopamine and norepinephrine reuptake inhibitor, helps in the treatment of addiction and ADHD. Agomelatine, a melatonin receptor agonist, has been shown to regulate diurnal rhythms, making it useful in the treatment of insomnia and other sleep disorders.   Aim of the Study The aim of this study is to analyse the use of amitriptyline, bupropion and agomelatine in the treatment of conditions other than depression, with a focus on their mechanisms of action and clinical efficacy.   Materials and Methods An analysis of PubMed papers was conducted using keywords: antidepressants, tricyclic antidepressants, SSRI, amitriptyline, bupropion, agomelatine.   Basic Results Amitriptyline is highly effective in the treatment of neuropathic pain, migraines and insomnia due to its potent action on serotonin and histamine receptors. Bupropion is used in the treatment of nicotine addiction and ADHD, as it acts on the dopaminergic and noradrenergic systems to improve concentration and impulse control. Agomelatine, as a melatonin receptor agonist, is used to regulate diurnal rhythms, making it helpful in the treatment of sleep disorders and adaptation to time zone changes. Each of these drugs has unique properties that go beyond their primary use in depression. https://apcz.umk.pl/QS/article/view/58924antidepressantstricyclic antidepressantsSSRIamitriptylinebupropionagomelatine
spellingShingle Piotr Czerniak
Julia Buszek
Michał Medygrał
Przemysław Koszuta
Małgorzata Dydoń-Pikor
Katarzyna Pajdak-Gicala
Maciej Kawecki
Adrianna Antoszewska
Weronika Bargiel
Sylwia Buszek
Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indications
Quality in Sport
antidepressants
tricyclic antidepressants
SSRI
amitriptyline
bupropion
agomelatine
title Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indications
title_full Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indications
title_fullStr Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indications
title_full_unstemmed Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indications
title_short Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indications
title_sort use of amitriptyline bupropion and agomelatine in the treatment of non depressive disorders a review of mechanisms and therapeutic indications
topic antidepressants
tricyclic antidepressants
SSRI
amitriptyline
bupropion
agomelatine
url https://apcz.umk.pl/QS/article/view/58924
work_keys_str_mv AT piotrczerniak useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT juliabuszek useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT michałmedygrał useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT przemysławkoszuta useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT małgorzatadydonpikor useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT katarzynapajdakgicala useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT maciejkawecki useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT adriannaantoszewska useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT weronikabargiel useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications
AT sylwiabuszek useofamitriptylinebupropionandagomelatineinthetreatmentofnondepressivedisordersareviewofmechanismsandtherapeuticindications